EAU 2017: Variation in the use of active surveillance for low-risk prostate cancer

London, England (UroToday.com) At this afternoon’s EAU 2017 Active Surveillance for Low-Risk Prostate Cancer poster session, Dr. Loppenberg and colleagues from Boston, USA presented their research regarding variation in the use of active surveillance (AS) for low risk prostate cancer. With recent reports suggesting an uptake worldwide in AS for low risk prostate cancer, further evaluating institutional factors associated with receipt of AS is important.

The authors utilized the US National Cancer Data Base (NCDB) to identify 40,215 men with low-risk prostate cancer between 2012-2013 according to the National Comprehensive Cancer Network (NCCN) guidelines. During this time period, the overall rate of AS was 14%. When compared to Comprehensive Community Cancer Centers, patients treated at Community Cancer Programs (OR 2.74, 95%CI 1.94-3.88) and academic institutions (OR 2.50, 95%CI 1.77-3.54) had greater odds of receiving AS. Similarly, patients treated at very high volume facilities had higher odds of receiving AS compared to very low volume institutions (OR 3.50, 95%CI 1.84-6.68). Patient level and hospital level variables accounted for 41% of the variation in receipt of AS, while institution level factors accounted for 35% of variability.

At NCDB institutions in the United States, AS rates remain dismally low for patients with low risk prostate cancer. Compared to a recent study from Sweden [1], where the current utilization for AS for very low risk patients is 91% and 74% for low-risk patients, there is substantial room for improvement. Since academic and high volume prostate cancer centers seem to have improved utilization in the US, perhaps further education of community-level hospitals is necessary to increase AS rates and prevent overtreatment of disease that is highly unlikely to be life threatening.

1. Loeb S, Folkvaljon Y, Curnyn C, et al. Uptake of Active Surveillance for very-low-risk Prostate Cancer in Sweden. JAMA Oncol 2016 Oct 20 [Epub ahead of print].

Speaker(s): Bjorn Loppenberg, Division of Urologic Surgery and Center for Surgery and Public Health, Brigham and Women’s Hospital, Boston, USA

Co-Authors: D. Friedlander, A. Tam, N. Von Landenberg, P. Gild, J. Leow, A. Krasnova, A. Kibel, J. Noldus, M. Menon, M. Sun, Q-D. Trinh

Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto
Twitter: @zklaassen_md

at the #EAU17 - March 24-28, 2017- London, England

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.